GO
Loading...

Pharmaceuticals

More

  • Protections set up by the U.S. Food and Drug Administration called "risk evaluation and mitigation strategies", which can curb distribution of dangerous medicines, have been used to prevent generic drugmakers from getting the drugs in order to test their own versions, which is required to win FDA approval, the report from the Generic Pharmaceutical Association said.

  • GSK cuts earnings forecast after weak 2nd quarter Wednesday, 23 Jul 2014 | 9:28 AM ET

    LONDON— Drug maker GlaxoSmithKline has cut its full-year earnings expectations as it says its second-quarter profits were hit by currency moves and a fall in sales of its respiratory drugs. The company said Wednesday it expects 2014 earnings per share to be broadly similar to last year.

  • UPDATE 2-GSK warns on profits as weak lung drug sales hit Wednesday, 23 Jul 2014 | 9:12 AM ET

    LONDON, July 23- GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • Shire to spend about $225M on drug collaboration Wednesday, 23 Jul 2014 | 8:44 AM ET

    The drugmaker Shire plans to spend about $225 million in a joint effort with a privately held, U.S. firm to develop a potential treatment for the rare and life-threatening genetic disorder Hunter syndrome.

  • Ackman goes after Herbalife's nutrition clubs Tuesday, 22 Jul 2014 | 4:00 PM ET

    NEW YORK— Activist investor Bill Ackman fired his latest salvo at the weight loss and nutritional supplements company Herbalife on Tuesday, alleging that one of the business models used by its distributors is evidence that the company operates as an illegal pyramid scheme.

  • Teary Ackman on HLF: Time to shut the company down Tuesday, 22 Jul 2014 | 2:40 PM ET

    Bill Ackman fired his latest shot at Herbalife Tuesday, but the company's stock mostly rose during the investor's presentation.

  • LONDON/ MUMBAI, July 22- Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline, five sources familiar with the matter said.

  • Ackman says Valeant-Allergan deal looks closer-CNBC Monday, 21 Jul 2014 | 1:11 PM ET

    July 21- Investor William Ackman, who owns nearly 10 percent of Botox maker Allergan Inc, said on Monday that the likelihood of Valeant Pharmaceuticals International Inc succeeding in its hostile takeover for Allergan increased on Monday.

  • Allergan to cut 1,500 employees in restructuring Monday, 21 Jul 2014 | 8:44 AM ET

    Botox maker Allergan will cut about 13 percent of its workforce as part of a push to become more efficient while it fights a hostile takeover bid from Valeant Pharmaceuticals. Allergan Inc. has rejected several takeover attempts from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman's Pershing Square Capital Management.

  • Valeant complains to regulators about Allergan Monday, 21 Jul 2014 | 7:07 AM ET
    Michael Pearson, CEO of Valeant Pharmaceuticals.

    Valeant has complained to regulators that claims made by Allergan to counter a hostile takeover are misleading, sources have told CNBC.

  • FedEx indictment shouldn't hurt shares, pro says Friday, 18 Jul 2014 | 4:41 PM ET
    A FedEx logo on a delivery truck

    FedEx's indictment for shipping packages from illegal online pharmacies isn't hurting shares, which makes sense to one analyst.

  • July 18- Valeant Pharmaceuticals Inc moved on Friday to blunt a key criticism by takeover target Allergan Inc of its Bausch+ Lomb business by releasing data showing strong sales growth.

  • July 18- Valeant Pharmaceuticals Inc moved on Friday to blunt a key criticism by takeover target Allergan Inc of its Bausch+ Lomb business by releasing data showing strong sales growth.

  • AbbVie, Shire agree on $55B combination Friday, 18 Jul 2014 | 6:43 AM ET

    The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home. But the new company will be controlled by shareholders of North Chicago, Illinois- based AbbVie, who will own about 75 percent of the new company's stock.

  • FedEx slapped with US charges over online drugs Friday, 18 Jul 2014 | 6:26 AM ET
    FedEx workers unload packages from a delivery truck in San Francisco, California.

    FedEx was indicted for shipping packages from illegal online pharmacies despite repeated warnings from U.S. drug enforcement officials.

  • WASHINGTON— Obama:' Eyes of the world on eastern Ukraine; We're going to make sure that truth gets out'.

  • Shire, Abbvie to announce merger shortly?     Friday, 18 Jul 2014 | 4:30 AM ET

    Surani Fernando, assistant editor at Biopharm Insight, says the market sees the latest Abbvie's takeover bid for Shire as fair and that the announcement of a merger should soon be made.

  • BEIJING, July 17- China will publicly prosecute a foreign couple linked to drugmaker GlaxoSmithKline Plc on charges of illegally obtaining private information, state media said. The announcement comes after the United States and Britain raised concerns about access to the trial.

  • UPDATE 2-Gambro acquisition boosts Baxter's sales Thursday, 17 Jul 2014 | 1:30 PM ET

    July 17- Medical device and drug maker Baxter International Inc reported higher-than-expected quarterly adjusted earnings, driven primarily by a surge in sales of the dialysis products it gained from its acquisition of Gambro AB last year.

  • July 17- Shire Plc and U.S. drugmaker Abbvie Inc plan to announce a $53 billion merger as soon as Friday morning, two people said on Thursday. Dublin- based Shire, which sells drugs for rare diseases, said earlier this week it was ready to recommend a deal to shareholders after AbbVie increased its offer.